Ionis Pharmaceuticals Files 8-K
Ticker: IONS · Form: 8-K · Filed: May 31, 2024 · CIK: 874015
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
Related Tickers: IONS
TL;DR
IONIS filed an 8-K, standard reporting, no new news.
AI Summary
Ionis Pharmaceuticals, Inc. filed an 8-K on May 31, 2024, to report other events and financial statements. The filing does not contain specific details about new material events, significant financial transactions, or executive changes that would typically be disclosed in a current report.
Why It Matters
This filing indicates Ionis Pharmaceuticals is fulfilling its reporting obligations with the SEC, but it does not disclose any new material information that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for reporting purposes and does not contain any new material information that would suggest an immediate risk.
Key Players & Entities
- IONIS PHARMACEUTICALS, INC. (company) — Registrant
- May 31, 2024 (date) — Date of report
- 2855 Gazelle Court Carlsbad, CA 92010 (address) — Principal Executive Offices
- 760-931-9200 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Ionis Pharmaceuticals?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of May 31, 2024.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is IONIS PHARMACEUTICALS, INC.
In which state was Ionis Pharmaceuticals incorporated?
Ionis Pharmaceuticals was incorporated in Delaware.
What is the principal executive office address for Ionis Pharmaceuticals?
The principal executive office address is 2855 Gazelle Court, Carlsbad, CA 92010.
Does this filing indicate any immediate material changes or events for Ionis Pharmaceuticals?
No, this filing is a standard current report and does not specify any new material events or changes that would require immediate disclosure beyond routine reporting.
Filing Stats: 425 words · 2 min read · ~1 pages · Grade level 10.1 · Accepted 2024-05-31 07:15:31
Filing Documents
- ef20030319_8k.htm (8-K) — 24KB
- ef20030319_ex99-1.htm (EX-99.1) — 44KB
- image0.jpg (GRAPHIC) — 24KB
- image00001.jpg (GRAPHIC) — 43KB
- 0001140361-24-028247.txt ( ) — 303KB
- ions-20240531.xsd (EX-101.SCH) — 4KB
- ions-20240531_lab.xml (EX-101.LAB) — 21KB
- ions-20240531_pre.xml (EX-101.PRE) — 16KB
- ef20030319_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On May 31, 2024, Ionis Pharmaceuticals, Inc. issued a press release announcing positive results from the OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE). A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated May 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Ionis Pharmaceuticals, Inc. Dated: May 31, 2024 By: /s/Patrick R. O'Neil Patrick R. O'Neil Executive Vice President, Chief Legal Officer and General Counsel